Boston Scientific closes Neovasc transaction

|About: Boston Scientific Corp... (BSX)|By:, SA News Editor

Boston Scientific (NYSE:BSX) finalizes its acquisition of certain manufacturing assets and capabilities of Neovasc's (NASDAQ:NVCN) advanced biological tissue business along with an equity investment for a total of $75M in cash.

Previously: Neovasc up 95% premarket on Boston Scientific investment (Dec. 2)